RYVYX
Price
$737.77
Change
+$3.04 (+0.41%)
Updated
Dec 3 closing price
Net Assets
1.58B
UOPSX
Price
$100.87
Change
+$1.63 (+1.64%)
Updated
Dec 2 closing price
Net Assets
1.69B
Interact to see
Advertisement

RYVYX vs UOPSX

Header iconRYVYX vs UOPSX Comparison
Open Charts RYVYX vs UOPSXBanner chart's image
Rydex NASDAQ-100® 2x Strategy H
Price$737.77
Change+$3.04 (+0.41%)
VolumeN/A
Net Assets1.58B
ProFunds UltraNASDAQ-100 Svc
Price$100.87
Change+$1.63 (+1.64%)
VolumeN/A
Net Assets1.69B
RYVYX vs UOPSX Comparison Chart in %
View a ticker or compare two or three
VS
RYVYX vs. UOPSX commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RYVYX is a Buy and UOPSX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
UOPSX has more cash in the bank: 1.69B vs. RYVYX (1.58B). RYVYX (0.00) and UOPSX (0.00) have matching dividends . RYVYX was incepted earlier than UOPSX: RYVYX (26 years) vs UOPSX (28 years). UOPSX (2.53) is less costly to investors than RYVYX (1.87). RYVYX is a more actively managed with annual turnover of: 383.00 vs. UOPSX (22.00). RYVYX has a lower initial minimum investment than UOPSX: RYVYX (2500) vs UOPSX (15000). UOPSX annual gain was more profitable for investors over the last year : 24.05 vs. RYVYX (21.89). RYVYX return over 5 years is better than : 112.91 vs. UOPSX (60.43).
RYVYXUOPSXRYVYX / UOPSX
Total Expense Ratio1.742.5369%
Annual Report Gross Expense Ratio1.872.5374%
Fund Existence26 years28 years-
Gain YTD31.36026.900117%
Front LoadN/AN/A-
Min. Initial Investment25001500017%
Min. Initial Investment IRAN/AN/A-
Net Assets1.58B1.69B94%
Annual Yield % from dividends0.000.00-
Returns for 1 year21.8924.0591%
Returns for 3 years214.90190.81113%
Returns for 5 years112.9160.43187%
Returns for 10 years746.42572.04130%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ENGGF16.20N/A
N/A
Enagas S.A.
ALPMF12.23N/A
N/A
Astellas Pharma, Inc.
AVNBF23.40N/A
N/A
AVON TECHNOLOGIES PLC
HOFBF0.17N/A
N/A
Hofseth Biocare ASA
FNTTF0.26N/A
N/A
XR IMMERSIVE TECH INC.